has had a roller coaster week, with the stock getting a boost from a coverage initiation at Cowen and then falling, along with the rest of the cannabis sector, after the announcement of the pending resignation of U.S. Food and Drug Administration head Scott Gottlieb. Gottlieb's departure leaves the fate of CBD products in doubt until a new commissioner is found for the regulatory agency. In December, Gottlieb signed the Agriculture Improvement Act, which removed hemp from the Controlled Substances Act, paving the way for CBD products derived from hemp to be sold legally.